The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL

Francesco Carinci, Lorenzo Monasta, Corrado Rubini, Daniela Stramazzotti, Annalisa Palmieri, Elisabetta Melloni, Alex Knowles, Luca Ronfani, Giorgio Zauli, Paola Secchiero

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)810-818
Number of pages9
JournalInvestigational New Drugs
Issue number2
Publication statusPublished - Apr 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this